{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:29Z","timestamp":1789398269199,"version":"build-2803163510"},"reference-count":5,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p> Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment option in systemic lupus erythematosus with potential applicability to discoid lupus erythematosus. We describe a 48-year-old woman with multiple treatment-refractory scalp plaques and associated alopecia treated with deucravacitinib. She demonstrated resolution of symptoms and 1\u20132 cm hair regrowth at a 3-month follow-up, with significant hair regrowth and reduction in plaque size at a 6-month follow-up. The patient tolerated the medication well with no side effects. This case highlights the potential of deucravacitinib as an effective therapy for refractory discoid lupus erythematosus. <\/jats:p>","DOI":"10.1177\/2050313x241304891","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T11:50:28Z","timestamp":1735818628000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-1909","authenticated-orcid":false,"given":"Katherine","family":"Aw","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gavigan","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada"},{"name":"Division of Dermatology, Children\u2019s Hospital of Eastern Ontario, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"bibr1-2050313X241304891","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8"},{"key":"bibr2-2050313X241304891","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103440"},{"key":"bibr3-2050313X241304891","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"bibr4-2050313X241304891","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.04.032"},{"key":"bibr5-2050313X241304891","unstructured":"ClinicalTrials.gov. A study to evaluate efficacy and safety of deucravacitinib in participants with active discoid and\/or subacute cutaneous lupus erythematosus (DLE\/SCLE), ClinicalTrials.gov identifier: NCT04857034, https:\/\/clinicaltrials.gov\/study\/NCT04857034 (2024, accessed 1 March 2024)."}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X241304891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X241304891","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X241304891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T01:58:44Z","timestamp":1740880724000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X241304891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":5,"alternative-id":["10.1177\/2050313X241304891"],"URL":"https:\/\/doi.org\/10.1177\/2050313x241304891","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"2050313X241304891"}}